Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

2.740
-0.040-1.44%
Volume:13.80M
Turnover:37.66M
Market Cap:10.95B
PE:21.84
High:2.760
Open:2.760
Low:2.700
Close:2.780
52wk High:4.490
52wk Low:1.670
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:0.93
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.125
ROE:3.68%
ROA:2.41%
PB:0.66
PE(LYR):21.84
PS:1.57

Loading ...

Luye Pharma Group Ltd. (02186) Announces January 2026 Monthly Return on Movements in Securities

Bulletin Express
·
Feb 05

China Cinda Subsidiaries to Inject 285 Million Yuan into Luye Pharma Unit

MT Newswires Live
·
Jan 27

LUYE PHARMA (02186) Shareholder Transfers HK$454 Million Worth of Shares from CCB International Securities to UBS Securities Hong Kong

Stock News
·
Jan 27

LUYE PHARMA (02186): Nanjing LUYE Pharma Secures RMB 285 Million Capital Injection

Stock News
·
Jan 27

Luye Pharma (02186) Announces RMB285 Million Capital Injection in Nanjing Luye, Triggering Discloseable and Connected Transaction

Bulletin Express
·
Jan 27

Luye Pharma - Nanjing Xinan, Ningbo Cinda to Provide Further Capital to Nanjing Luye for Total RMB285 Mln on Jan 26

THOMSON REUTERS
·
Jan 27

Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi

Reuters
·
Jan 27

Shandong Boan Biotechnology Transfers 11.99 Million H Shares to Complete Minority Stake Deal

Reuters
·
Jan 26

BOAN BIOTECH (06955): Shandong Luye Pharmaceutical Plans Further Transfer of 38.5 Million H Shares to Luye Geneora Holding

Stock News
·
Jan 21

Shandong Boan Biotechnology Transfers 38.5 Million H Shares to New Investor

Reuters
·
Jan 21

A Look At Luye Pharma Group (SEHK:2186) Valuation After Ruoxinlin NDA Acceptance For Anxiety Disorder

Simply Wall St.
·
Jan 15

Shandong Boan Biotechnology Signs Finance Lease Agreement with Industrial Bank Financial Leasing

Reuters
·
Jan 14

LUYE PHARMA (02186): NDA for New Indication of Class 1 Innovative Drug Ruoxinlin® for Generalized Anxiety Disorder Accepted in China

Stock News
·
Jan 08

Luye Pharma - New Drug Application for Class 1 Innovative Drug Ruoxinlin for New Indication of Generalized Anxiety Disorder Accepted in China

THOMSON REUTERS
·
Jan 08

China Accepts Luye Pharma's NDA for Ruoxinlin in Generalized Anxiety Disorder

Reuters
·
Jan 08

Luye Pharma (02186): Xia Lian Appointed as Member of Nomination Committee

Stock News
·
Dec 31, 2025

Luye Pharma Appoints Xia Lian to Nomination Committee

Reuters
·
Dec 31, 2025

LUYE PHARMA (02186) Grants Exclusive Commercialization Rights for Three Long-Acting Antipsychotic Injections to Enhua in Mainland China

Stock News
·
Dec 24, 2025

Luye Pharma - Certain Units Entered Agreement With Jiangsu Nhwa Hexin Pharmaceutical Marketing

THOMSON REUTERS
·
Dec 24, 2025

Luye Pharma - Grant of Commercialization Rights to Nhwa for 3 Long-Acting Injectable Antipsychotics in China

THOMSON REUTERS
·
Dec 24, 2025